Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes

British Journal of Cancer

Volumn 87, Issue 1, 2002, Pages 21-27

  Tsavaris, N ^a   Kosmas, C ^a   Vadiaka, M ^a   Kanelopoulos, P ^a   Boulamatsis, D ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Breast cancer; Cytokines; Docetaxel; Immune; Paclitaxel

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKINE; DOCETAXEL; ESTROGEN RECEPTOR; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; PACLITAXEL; PROGESTERONE RECEPTOR; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNE RESPONSE; LYMPHOKINE ACTIVATED KILLER CELL; MIXED LYMPHOCYTE REACTION; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; ANTIBODY FORMATION; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GROWTH SUBSTANCES; HUMANS; IMMUNITY, CELLULAR; KILLER CELLS, LYMPHOKINE-ACTIVATED; MIDDLE AGED; PACLITAXEL; TAXOIDS;

EID: 0036649794     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600347     Document Type: Article

References (27)

1. Docetaxel
2. Colchicine has opposite effects on interleukin-1 beta and tumor necrosis factor-alpha production
3. Taxol enhances but does not induce interleukin-1 beta and tumor necrosis factor-alpha production
4. The intracellular precursor of IL-1 beta is associated with microtubules in activated U937 cells
5. Decreased HLA-DR antigen expression on monocytes causes impaired suppressor cell activity in multiple sclerosis
6. Tumor specific cytolysis by tumor-infiltrating lymphocytes in breast cancer
7. Granulocyte-macrophage colony-stimulating factor improves immunological parameters in patients with refractory solid tumours receiving second-line chemotherapy: Correlation with clinical responses
8. Increased generation of autologous tumor-reactive lymphocytes by anti-CD3 monoclonal antibody and prothymosin α
9. Tumor specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor
10. Taxol, a microtubule-stabilizing antineoplastic agent, induces expression of tumor necrosis factor alpha and interleukin-1 in macrophages
11. The immunological effects of taxenes
12. Shared actions of endotoxin and taxol on TNF receptors and TNF release
13. Docetaxel treatment of HT-29 colon carcinoma cells reinforces the adhesion and immunocytotoxicity of peripheral blood lymphocytes in vitro
14. Docetaxel-induced lymphopenia in patients with solid tumors
15. IL-8 reduced tumorigenecity of human ovarian cancer in vivo due to neutrophil infiltration
16. Paclitaxel causes mouse splenic lymphocytes to a state hyporesponsive to lipopolysaccharide stimulation
17. Paclitaxel-induced immune suppression is associated with NF-kappaB activation via conventional PKC isotypes in lipopolysaccharide-stimulated 70Z/3 pre-B lymphocyte tumor cells
18. Taxing and taxanes: Overused or undersold?
19. Reporting results of cancer treatment
20. Interleukin-12 overcomes paclitaxel-mediated suppression of T-cell proliferation
21. Taxol stabilizes microtubules in mouse fibroblast cells
22. Cellular immune profile of patients with advanced cancer before and after taxane treatment
23. The prognostic significance of immune changes in patients with renal cancer, melanoma and colorectal cancer, treated with interferon alpha 2b
24. A feasibility study of 1-hour paclitaxel infusion in solid tumors
25. Taxanes: An overview of the pharmacokinetics and pharmacodynamics